ABVX vs QNRX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABVX and QNRX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABVX and QNRX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the pivotal Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo. Management has guided toward a U.S. FDA new drug application filing in late 2026, with a Phase 2b Crohn's disease readout expected around mid-2027.

Full ABVX guide

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company, domiciled in Israel and listed in the US as American Depositary Shares, that develops treatments for rare and orphan diseases. Its lead asset is QRX003, a topical lotion designed as a serine protease inhibitor for Netherton Syndrome, a rare and often life-threatening inherited skin disease. QRX003 has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the US FDA, plus Orphan Drug designation in the European Union and Japan, and the company has reported an FDA-conditionally-accepted proposed brand name. Because Quoin has no approved products, it generates essentially no product revenue and instead spends on research, clinical trials, and operations, so it is best understood as a research-stage venture rather than an operating business.

Full QNRX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABVX drivers: Positive Phase 3 obefazimod data; Path to an FDA filing.
• QNRX drivers: QRX003 and the Netherton Syndrome opportunity; Orphan drug designations and regulatory incentives.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. For QNRX, quoin carries the full risk set of an early-stage, single-asset biotech.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABVX if you believe its drivers more; QNRX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABVX and QNRX guides.

ABVX. Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding pivotal trials rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.

QNRX. These points are qualitative and tied to the asOf date; Quoin has no meaningful revenue or earnings to value on standard multiples, so traditional metrics like P/E do not apply. For a pre-revenue biotech, valuation is driven by the probability-weighted potential of the pipeline and by cash runway, both of which shift with every trial readout and financing. Always verify the latest cash position, share count, and clinical timelines directly from the company's filings before acting.

Headline figures (approximate, July 2026): ABVX shows market cap ~$7-8B, product revenue (ttm) ~negligible (pre-commercial), net loss (fy2025) ~EUR 336M, r&d expense (fy2025) ~EUR 178M; QNRX shows product revenue Effectively none; Quoin is pre-commercial with no approved products (verify latest filings), profitability Operating at a loss, typical of a clinical-stage developer funding R&D and trials, lead program stage QRX003 for Netherton Syndrome; pivotal Phase 3 expected to begin in H2 2026 per company statements, cash / financing Disclosed a private placement financing in late 2025 to fund operations and R&D; check current cash runway.

ABVX and QNRX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABVX and QNRX exposure against your real portfolio. It is not an investment adviser.